Czech Rep taken to task by EU over failure to transpose blood regs
This article was originally published in Clinica
Executive Summary
The European Court of Justice has found against the Czech Republic for its failure to transpose Directive 2004/33/EC - Technical requirements for blood and blood components - within the time limit. The judgement was published in the Official Journal of the European Union on December 12 2007. The Czech Republic was ordered to pay the costs in the case.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.